Related Experiment Video
Updated: Feb 27, 2026

Efficient and Scalable Production of Full-length Human Huntingtin Variants in Mammalian Cells using a Transient Expression System
Published on: December 10, 2021
What do we know about Late Onset Huntington's Disease?
Sai S Chaganti1,2, Elizabeth A McCusker1,2, Clement T Loy1,3,4
1Huntington Disease Service, Westmead Hospital, Sydney, Australia.
Late onset Huntington's disease (LoHD) affects 4.4-11.5% of individuals and can be missed due to atypical presentation. LoHD may present with non-motor symptoms and have a slower progression, impacting diagnosis.
Area of Science:
- Neurology
- Genetics
- Epidemiology
Background:
- Huntington's disease (HD) typically manifests in the fourth decade.
- Late onset Huntington's disease (LoHD), defined as onset over 60 years, accounts for 4.4-11.5% of HD cases.
- Diagnosis of LoHD can be challenging due to its lower perceived prevalence in older adults.
Purpose of the Study:
- To review the epidemiology, genotype, and phenotype of Late onset Huntington's disease (LoHD).
Main Methods:
- Systematic literature search of MEDLINE, EMBASE, and Web of Science databases (inception-November 2016).
- Inclusion of studies reporting clinical phenotype of LoHD for more than one participant.
- Consultation with content experts for additional studies.
Main Results:
- 20 studies were identified, revealing LoHD constitutes a significant proportion of HD cases, potentially increasing.
- CAG repeat lengths in LoHD are typically ≤44, with variable family history presentation (3-68%).
- While motor symptoms are common, 29.2% of cases present with non-motor features; cognitive impairment may be a primary source of disability, and progression may be slower.
Conclusions:
- Late onset Huntington's disease (LoHD) represents a substantial portion of new HD diagnoses and exhibits unique characteristics.
- Further research into LoHD populations is crucial for improving clinical diagnosis and management.
Related Concept Videos
Parkinson's Disease: Overview
Alzheimer's Disease: Overview
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
Parkinson's Disease: Treatment
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Lysosomal Hydrolases
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Genetic Lingo

